Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2019

01-05-2019 | Acute Myeloid Leukemia | Original Article

Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia

Authors: Nana Arai, Mayumi Homma, Maasa Abe, Yuta Baba, So Murai, Megumi Watanuki, Yukiko Kawaguchi, Shun Fujiwara, Nobuyuki Kabasawa, Hiroyuki Tsukamoto, Yui Uto, Hirotsugu Ariizumi, Kouji Yanagisawa, Norimichi Hattori, Bungo Saito, Eisuke Shiozawa, Hiroshi Harada, Toshiko Yamochi-Onizuka, Tsuyoshi Nakamaki, Masafumi Takimoto

Published in: International Journal of Hematology | Issue 5/2019

Login to get access

Abstract

Aberrant expression of the interleukin-3 receptor alpha chain (IL3RA or CD123) is frequently observed in patients with a subset of leukemic disorders, including acute myeloid leukemia (AML), particularly in leukemia stem cells. We analyzed the relationships between immunohistochemical (IHC) expression, including that of CD123, and clinical outcomes. This study involved a retrospective analysis of 48 patients diagnosed with de novo AML (M0–M5, n = 48) at our hospital between February 2008 and September 2015. Among patients with de novo AML, CD123 expression was associated with a failure to achieve complete response (CR) to initial induction chemotherapy (P = 0.044) and poor overall survival (OS) (P = 0.036). This is the first study using IHC to demonstrate that CD123 expression is associated with a poor CR rate and poor OS in de novo AML patients. These results support previous reports using flow cytometry (FCM). CD123 expression may thus be useful for assessing AML patients’ prognoses. At the time of diagnosis, CD123 expression analysis using IHC may represent a clinically useful assessment for de novo AML patients.
Literature
1.
Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. Interleukin-3 receptor in acute leukemia. Leukemia. 2004;18:219–26.CrossRefPubMed
2.
3.
Muñoz L, Nomdedéu JF, López O, Carnicer MJ, Bellido M, Aventín A, et al. Interleukin-3 receptor α chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261–9.PubMed
4.
Ihle JN. Interleukin-3 and hematopoiesis. Chem Immunol. 1992;51:65–106.PubMed
5.
Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia Aug. 1999;13:1109–66.CrossRef
6.
Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980–8.CrossRefPubMed
7.
Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2003;21:212–7.
8.
Fernandez-Pol S, Ma L, Ohgami RS, Arber DA. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis. Mod Pathol. 2017;30:382–92.CrossRefPubMed
9.
Hou HA, Chou WC, Kuo YY, Liu CY, Lin LI, Tseng MH, et al. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution. Blood Cancer J. 2015;5:e331.CrossRefPubMedPubMedCentral
10.
Orazi A, Cattoretti G, Heerema NA, Sozzi G, John K, Neiman RS. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. Mod Pathol. 1993;6:521–5.PubMed
11.
McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016;101:e320.CrossRefPubMedPubMedCentral
12.
Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34 + CD38 low/-CD123 + blasts are predictive of an adverse outcome in acute myeloid leukemia: a groupeouest-est des leucémiesaiguës et maladies du sang (GOELAMS) study. Haematologica. 2011;96:1792–8.CrossRefPubMedPubMedCentral
13.
Robert CB Jr, Daniel PR, Susan FH, Herbert B, John F Jr MJ, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865–78.CrossRef
14.
Hattori N, Fukuchi K, Nakamaki T, Homma M, Ariizumi H, Nakashima H, et al. P53 protein expression in chronic myelomonocytic leukemia-1 correlates with progression to leukemia and a poor prognosis. Acta Haematol. 2011;125:242–6.CrossRefPubMed
15.
Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H, et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. Pathol Int. 2008;58:353–60.CrossRefPubMed
16.
Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38–/CD123 + delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016;9:61.CrossRefPubMedPubMedCentral
17.
Ehninger A, Kramer M, Röllig C, Thiede C, Bornhäuser M, von Bonin M,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.CrossRefPubMedPubMedCentral
18.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.CrossRefPubMed
19.
Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells: research paper. Br J Haematol. 2010;148:879–89.CrossRefPubMed
20.
Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene. 2011;30:1009–19.CrossRefPubMed
21.
Hanekamp D, Closs J, Schuurhuis GJ. Leukemia stem cells; identification and clinical application. Int J Hematol. 2017;105:549–57.CrossRefPubMed
22.
Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell—directed dual-affinity retargeting platform. Blood. 2016;127:122–32.CrossRefPubMedPubMedCentral
23.
Li G, Li X, Wu H, Yang X, Zhang Y, Chen L, et al. CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo. Blood Cancer J. 2014;4:194.CrossRef
24.
Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401.CrossRefPubMed
25.
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28:1596–605.CrossRefPubMed
26.
Moradi-Kalbolandi S, Habibi-Anbouhi M, Golkar M, Behdani M, Rezaei G, Ghazizadeh L, et al. Development of a novel engineered antibody targeting human CD123. Anal Biochem. 2016;511:27–30.CrossRefPubMed
27.
Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.CrossRefPubMedPubMedCentral
28.
Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;1:31–42.CrossRef
29.
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124:385–92.CrossRefPubMedPubMedCentral
Metadata
Title
Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia
Authors
Nana Arai
Mayumi Homma
Maasa Abe
Yuta Baba
So Murai
Megumi Watanuki
Yukiko Kawaguchi
Shun Fujiwara
Nobuyuki Kabasawa
Hiroyuki Tsukamoto
Yui Uto
Hirotsugu Ariizumi
Kouji Yanagisawa
Norimichi Hattori
Bungo Saito
Eisuke Shiozawa
Hiroshi Harada
Toshiko Yamochi-Onizuka
Tsuyoshi Nakamaki
Masafumi Takimoto
Publication date
01-05-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02616-y

Other articles of this Issue 5/2019

International Journal of Hematology 5/2019 Go to the issue

Case Report

Vitamin C deficiency: rare cause of severe anemia with hemolysis

Correction

Correction to: Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol

Case Report

Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma

Original Article

Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series

Original Article

Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele

Letter to the Editor

Numerous Russell bodies in multiple myeloma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits